【摘要】 目的:观察阿托伐他汀治疗非瓣膜病阵发性心房颤动的效果。方法:76例非瓣膜病阵发性心房颤动患者,随机分为治疗组(阿托伐他汀加胺碘酮,37例)及对照组(单用胺碘酮,39例),观察6个月,比较两组的C反应蛋白(CRP)水平、复发率及不良反应。结果:治疗组的CRP水平较对照组明显减少[(18.31±5.09)ng/ml∶(33.28±6.43)ng/ml,P<0.05]。治疗组复发率24.3%(9/37),显著低于对照组的48.7%(19/39),P<0.05。结论:阿托伐他汀可抑制炎症反应,减少阵发性房颤的复发。更多还原

【Abstract】 Objective:To observe the therapeutic effect of atorvastatin on paroxysmal atrial fibrillation in patients with nonvalvular disease.Methods:The 76 patients with nonvalvular disease complicated with paroxysmal atrial fibrillation were randomly divided into two groups:treatment group[37 cases,treated by atorvastatin(20mg/d) combined with amiodarone];control group(39 cases,treated by amiodarone only).A treatment course was six months for two groups.The C reactive protein(CRP) and the rate of recrudescence,adverse reaction in both groups were observed.Results: The recrudescence rates were 24.3%(9/37) in treatment group,it was significantly decreased,than that of control group 48.7%(19/39),P<0.05.The CRP level significantly devreased in treatment group than that in control group[(18.31±5.09)ng/ml vs.(33.28±6.43)ng/ml P<0.05].Conclusion:Atorvastatin can inhibit inflammation and reduce the recrudescence of paroxysmal atrial fibrillation in patients with nonvalvular disease.更多还原